REACT-AUS: REsistant And Hard-to-Control HyperTension in AUStralia

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000943
• Study ID:
  1000000943
• Official title and acronym:
  REACT-AUS: REsistant And Hard-to-Control HyperTension in AUStralia
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  This is a real-world observational study using primary care data from Australia (Optimum Patient Care Research Database Australia [OPCRDA]) to (1) quantify prescribing patterns and treatment trajectories of hypertension patients over time and how they align with Guidelines Directed Medical Therapy (GDMT) (2) To explore factors that drive treatment choices for hard-to-control/resistant hypertension (3) To quantify the prevalence of hard-to-control/resistant hypertension and length of time with hypertension before meeting hard-to-control/resistant status ; ; All adults (≥18 years and <85 years) with high blood pressure measurement (systolic blood pressure ≥140mmHg and/or diastolic blood pressure≥90mmHg) with ≥2 antihypertension treatments in the previous 1–4 months between 2006 and 2025 will be identified. For hard-to-control hypertension, index date will be the first date of a high blood pressure measurement with ≥2 antihypertensive therapies in the previous 1–4 months. For resistant hypertension, index date will be the first date of a high blood pressure measurement with ≥3 antihypertensive therapies in the previous 1–4 months. The same patient can be included as having hard-to-control and resistant hypertension where they step up from 2 antihypertensive therapies, but their blood pressure remains uncontrolled. ; ; We will investigate characteristics of patients within the first 12 months of receiving their first hard-to-control and/or resistant hypertension event in the observation window. Patients will be followed up for a maximum of 12 months from their hard-to-control/resistant blood pressure measurement.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Optimum Patient Care Australia (OPCA)

Study timelines

Date when funding contract was signed

Planned:13/11/2025

Actual:13/11/2025

Study start date

Planned:31/01/2026

Actual:31/01/2026

Data analysis start date

Planned:12/02/2026

Date of final study report

Planned:31/03/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca Australia, Optimum Patient Care Australia and Observational & Pragmatic Research Institute

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable